EDESA BIOTECH, INC. Increase (Decrease) in Accounts and Other Receivables
EDESA BIOTECH, INC. (EDSA) reported Increase (Decrease) in Accounts and Other Receivables of -$412.59 thousand for the 9-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables · last filed 2026-08-13
- EDESA BIOTECH, INC. increase (decrease) in accounts and other receivables for the quarter ending 2026-06-30 was $16.14K.
- EDESA BIOTECH, INC. increase (decrease) in accounts and other receivables for the quarter ending 2026-03-31 was -$211.34K, a 784.61% decline year-over-year.
- EDESA BIOTECH, INC. increase (decrease) in accounts and other receivables for the quarter ending 2025-12-31 was -$217.39K, a 322.52% decline year-over-year.
- EDESA BIOTECH, INC. increase (decrease) in accounts and other receivables for the quarter ending 2025-09-30 was $359.83K.
- EDESA BIOTECH, INC. increase (decrease) in accounts and other receivables for fiscal 2025 was $377.99K.
- EDESA BIOTECH, INC. increase (decrease) in accounts and other receivables for fiscal 2024 was -$356.34K.
- EDESA BIOTECH, INC. increase (decrease) in accounts and other receivables for fiscal 2023 was -$562.77K.
- EDESA BIOTECH, INC. increase (decrease) in accounts and other receivables for fiscal 2022 was -$2.03M.
| Period end | Increase (Decrease) in Accounts and Other Receivables 3 month | Increase (Decrease) in Accounts and Other Receivables 3 month as first filed | Increase (Decrease) in Accounts and Other Receivables 6 month | Increase (Decrease) in Accounts and Other Receivables 9 month | Increase (Decrease) in Accounts and Other Receivables 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $16.14K derived: 10-Q 9 month − 10-Q 6 month · filed 2026-08-13 | -$195.21K derived: sum of 2 quarters · filed 2026-08-13 | -$412.59K 10-Q · filed 2026-08-13 | -$52.76K derived: sum of 4 quarters · filed 2026-08-13 | |
| 2026-03-31 | -$211.34K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-05-14 | -$428.73K 10-Q · filed 2026-05-14 | -$68.90K derived: sum of 3 quarters · filed 2026-05-14 | -$179.31K derived: sum of 4 quarters · filed 2026-08-13 | |
| 2025-12-31 | -$217.39K 10-Q · filed 2026-02-13 | $142.44K derived: sum of 2 quarters · filed 2026-02-13 | $32.04K derived: sum of 3 quarters · filed 2026-08-13 | $62.91K derived: sum of 4 quarters · filed 2026-08-13 | |
| 2025-09-30 | $359.83K derived: 10-K 12 month − 10-Q 9 month · filed 2025-12-12 | $249.42K derived: sum of 2 quarters · filed 2026-08-13 | $280.30K derived: sum of 3 quarters · filed 2026-08-13 | $377.99K 10-K · filed 2025-12-12 | |
| 2025-06-30 | -$110.40K derived: 10-Q 9 month − 10-Q 6 month · filed 2026-08-13 | -$79.53K derived: sum of 2 quarters · filed 2026-08-13 | $18.16K 10-Q · filed 2026-08-13 | -$266.68K derived: sum of 4 quarters · filed 2026-08-13 | |
| 2025-03-31 | $30.87K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-05-14 | $128.56K 10-Q · filed 2026-05-14 | -$156.28K derived: sum of 3 quarters · filed 2026-05-14 | -$711.89K derived: sum of 4 quarters · filed 2026-05-14 | |
| 2024-12-31 | $97.69K 10-Q · filed 2026-02-13 | -$187.15K derived: sum of 2 quarters · filed 2026-02-13 | -$742.76K derived: sum of 3 quarters · filed 2026-02-13 | -$358.23K derived: sum of 4 quarters · filed 2026-02-13 | |
| 2024-09-30 | -$284.84K derived: 10-K 12 month − 10-Q 9 month · filed 2025-12-12 | -$840.45K derived: sum of 2 quarters · filed 2025-12-12 | -$455.92K derived: sum of 3 quarters · filed 2025-12-12 | -$356.34K 10-K · filed 2025-12-12 | |
| 2024-06-30 | -$555.61K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-08-08 | -$171.09K derived: sum of 2 quarters · filed 2025-08-08 | -$71.50K 10-Q · filed 2025-08-08 | $514.86K derived: sum of 4 quarters · filed 2025-08-08 | |
| 2024-03-31 | $384.52K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-05-14 | $484.11K 10-Q · filed 2025-05-14 | $1.07M derived: sum of 3 quarters · filed 2025-05-14 | $1.06M derived: sum of 4 quarters · filed 2025-05-14 | |
| 2023-12-31 | $99.58K 10-Q · filed 2025-02-14 | -$99.58K 10-Q · filed 2024-02-09 | $685.94K derived: sum of 2 quarters · filed 2025-02-14 | $674.65K derived: sum of 3 quarters · filed 2025-02-14 | -$1.52M derived: sum of 4 quarters · filed 2025-02-14 |
| 2023-09-30 | $586.36K derived: 10-K 12 month − 10-Q 9 month · filed 2024-12-13 | $575.06K derived: sum of 2 quarters · filed 2024-12-13 | -$1.62M derived: sum of 3 quarters · filed 2024-12-13 | -$562.77K 10-K · filed 2024-12-13 | |
| 2023-06-30 | -$11.30K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-08-09 | -$2.21M derived: sum of 2 quarters · filed 2024-08-09 | -$1.15M 10-Q · filed 2024-08-09 | ||
| 2023-03-31 | -$2.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-05-10 | -$1.14M 10-Q · filed 2024-05-10 | |||
| 2022-12-31 | $1.06M 10-Q · filed 2024-02-09 | ||||
| 2022-09-30 | -$2.03M 10-K · filed 2023-12-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B |